Skip to content

Replimune Group REPL Change in Other Liabilities

Change in Other Liabilities at other companies

Amgen logo
AmgenAMGN
-$75M+3.8%
CG Oncology logo
CG OncologyCGON
-$329K
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$384K+225%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$16M+5.9%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$33K-232%
Roivant Sciences logo
Roivant SciencesROIV
-$252K-230%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's change in other liabilities?
Replimune Group (REPL) reported change in other liabilities of -$268K in Q4 2025.
How has Replimune Group's change in other liabilities changed year-over-year?
Replimune Group's change in other liabilities decreased by 155.8% year-over-year, from $480K to -$268K.
What does change in other liabilities mean?
Change in miscellaneous liabilities affecting operating cash flow.